Research Overview: Tafero EM 200/
Tafero EM 200/25 mg is a pharmaceutical combination tablet containing emtricitabine (200 mg) and tenofovir alafenamide (25 mg), two nucleoside reverse transcriptase inhibitors extensively studied in HIV virology research. This fixed-dose combination represents an important tool for investigating antiviral mechanisms and resistance patterns in laboratory settings. Researchers at Stroid UK Shop and affiliated institutions utilize this compound to examine nucleotide analogue incorporation into viral DNA synthesis pathways and evaluate combination therapy synergistic effects.
Laboratory Applications
Research teams investigate Tafero EM’s dual-mechanism approach in viral suppression studies. Emtricitabine functions as a cytosine nucleoside analogue that terminates DNA chain elongation, while tenofovir alafenamide serves as a prodrug delivering active tenofovir diphosphate intracellularly with enhanced tissue penetration profiles. Investigators examine these compounds individually and in combination to understand resistance mutation development, cross-resistance patterns, and pharmacokinetic interactions. Studies frequently compare this formulation against other pharmaceutical research compounds to evaluate relative efficacy profiles and tissue distribution characteristics. Research protocols often incorporate cell culture models, enzymatic assays, and molecular binding studies to characterize these agents’ mechanisms of action.
Technical Specifications
| Parameter | Value |
|---|---|
| Active Components | Emtricitabine 200mg, Tenofovir alafenamide 25mg |
| Molecular Class | Nucleoside/nucleotide reverse transcriptase inhibitors |
| Emtricitabine CAS | 143491-57-0 |
| Tenofovir alafenamide CAS | 379270-37-8 |
| Form | Pharmaceutical tablet |
| Research Applications | HIV virology, antiviral mechanisms, resistance studies |
| Storage Requirements | Room temperature, dry conditions |
| Supplier | stroidukshop.co.uk |
This pharmaceutical preparation enables comprehensive investigation of combination antiviral therapy mechanisms. Unlike research focusing on selective androgen receptor modulators or bioactive peptides, Tafero EM studies concentrate on nucleic acid metabolism and viral replication inhibition pathways.
Research Compliance Statement
Tafero EM 200/25 mg is supplied exclusively for legitimate laboratory research investigating antiviral mechanisms, resistance patterns, and combination therapy effects. This pharmaceutical compound is not intended for human consumption, clinical treatment, or therapeutic applications. Researchers must adhere to appropriate institutional protocols, safety guidelines, and regulatory requirements when handling this material. All studies should be conducted in properly equipped laboratory facilities with adequate safety measures and waste disposal procedures.
